Now showing items 1-8 of 8

    • Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs 

      Wang, Yuexiang; Marino-Enriquez, Adrian; Bennett, Richard R.; Zhu, Meijun; Shen, Yiping; Eilers, Grant; Lee, Jen-Chieh; Henze, Joern; Fletcher, Benjamin S.; Gu, Zhizhan; Fox, Edward A.; Antonescu, Cristina R.; Fletcher, Christopher D.M.; Guo, Xiangqian; Raut, Chandrajit P.; Demetri, George D.; van de Rijn, Matt; Ordog, Tamas; Kunkel, Louis M.; Fletcher, Jonathan A. (2014)
      Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS), and leiomyosarcoma (LMS), feature myogenic differentiation1–3. Here we report that intragenic deletion of the ...
    • Effect of gastrointestinal resection on sunitinib exposure in patients with GIST 

      de Wit, Djoeke; van Erp, Nielka P; Khosravan, Reza; Wiltshire, Robin; Allred, Randy; Demetri, George D; Guchelaar, Henk-Jan; Gelderblom, Hans (BioMed Central, 2014)
      Background: GIST patients often undergo GI-surgery. Previous studies have shown that imatinib and nilotinib exposures were decreased in GIST patients with prior major gastrectomy. We investigated whether major gastrectomy ...
    • Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948) 

      Raut, Chandrajit P; Boucher, Yves; Duda, Dan Gabriel; Morgan, Jeffrey Arnold; Quek, Richard; Ancukiewicz, Marek; Lahdenranta, Johanna; Eder, Joseph Paul; Demetri, George Daniel; Jain, Rakesh K. (Public Library of Science, 2012)
      Purpose: Jain Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing ...
    • Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors 

      Demetri, George Daniel; von Mehren, Margaret; Blanke, Charles D.; Van Den Abbeele, Annick Diane; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart George; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D.M.; Joensuu, Heikki (New England Journal of Medicine (NEJM/MMS), 2002)
      Background Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical ...
    • Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy 

      Choy, Edwin; Butrynski, James E; Harmon, David C; Morgan, Jeffrey A; George, Suzanne; Wagner, Andrew J; D’Adamo, David; Cote, Gregory M; Flamand, Yael; Benes, Cyril H; Haber, Daniel A; Baselga, Jose M; Demetri, George D (BioMed Central, 2014)
      Background: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess ...
    • Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma 

      Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T.; Anatone, Alex J.; Sicinska, Ewa T.; Fletcher, Jonathan A.; Demetri, George D.; Wagner, Andrew J. (Impact Journals LLC, 2016)
      Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced ...
    • A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments 

      Wagner, Michael J; Amodu, Leo Ismaila; Duh, Mei Sheng; Korves, Caroline; Solleza, Franco; Manson, Stephanie C; Diaz, José; Neary, Maureen P; Demetri, George D (BioMed Central, 2015)
      Background: Limited clinical data on real-world practice patterns are available for patients with metastatic/relapsed soft tissue sarcomas (STS). The primary objective of this study was to evaluate treatment patterns in ...
    • Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors 

      Tomasetti, Cristian; Demetri, George D; Parmigiani, Giovanni (F1000Research, 2013)
      Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) ...